SE81 Stock Overview
Develops a technology for managing animal pest populations through fertility control.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SenesTech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.08 |
| 52 Week High | US$25.44 |
| 52 Week Low | US$2.04 |
| Beta | 0.86 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -91.84% |
| 3 Year Change | -99.59% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| SE81 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | -0.9% |
| 1Y | -91.8% | -20.4% | 4.5% |
Return vs Industry: SE81 underperformed the German Pharmaceuticals industry which returned -32.1% over the past year.
Return vs Market: SE81 underperformed the German Market which returned -1% over the past year.
Price Volatility
| SE81 volatility | |
|---|---|
| SE81 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: SE81 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SE81's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 30 | Joel Fruendt | www.senestech.com |
SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait that limits reproduction of male and female rats. SenesTech, Inc. was incorporated in 2004 and is headquartered in Phoenix, Arizona.
SenesTech, Inc. Fundamentals Summary
| SE81 fundamental statistics | |
|---|---|
| Market cap | €5.29m |
| Earnings (TTM) | -€7.55m |
| Revenue (TTM) | €1.11m |
4.8x
P/S Ratio-0.7x
P/E RatioIs SE81 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SE81 income statement (TTM) | |
|---|---|
| Revenue | US$1.20m |
| Cost of Revenue | US$669.00k |
| Gross Profit | US$526.00k |
| Other Expenses | US$8.65m |
| Earnings | -US$8.12m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70 |
| Gross Margin | 44.02% |
| Net Profit Margin | -679.92% |
| Debt/Equity Ratio | 1.9% |
How did SE81 perform over the long term?
See historical performance and comparison